CALT vs. BCYC, EOLS, PHAT, LQDA, ENTA, ZYME, ORGO, OCUL, ANAB, and IGMS
Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Bicycle Therapeutics (BCYC), Evolus (EOLS), Phathom Pharmaceuticals (PHAT), Liquidia (LQDA), Enanta Pharmaceuticals (ENTA), Zymeworks (ZYME), Organogenesis (ORGO), Ocular Therapeutix (OCUL), AnaptysBio (ANAB), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry.
Calliditas Therapeutics AB (publ) vs.
Bicycle Therapeutics (NASDAQ:BCYC) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.
Bicycle Therapeutics presently has a consensus price target of $53.20, indicating a potential upside of 104.77%. Calliditas Therapeutics AB (publ) has a consensus price target of $79.00, indicating a potential upside of 352.20%. Given Calliditas Therapeutics AB (publ)'s higher probable upside, analysts plainly believe Calliditas Therapeutics AB (publ) is more favorable than Bicycle Therapeutics.
Calliditas Therapeutics AB (publ) has higher revenue and earnings than Bicycle Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bicycle Therapeutics had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 9 mentions for Bicycle Therapeutics and 3 mentions for Calliditas Therapeutics AB (publ). Bicycle Therapeutics' average media sentiment score of 0.33 beat Calliditas Therapeutics AB (publ)'s score of -0.36 indicating that Bicycle Therapeutics is being referred to more favorably in the media.
Bicycle Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.
Bicycle Therapeutics received 84 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 67.09% of users gave Bicycle Therapeutics an outperform vote while only 59.46% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Calliditas Therapeutics AB (publ) has a net margin of -43.26% compared to Bicycle Therapeutics' net margin of -801.45%. Bicycle Therapeutics' return on equity of -44.57% beat Calliditas Therapeutics AB (publ)'s return on equity.
77.9% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 10.2% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Bicycle Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calliditas Therapeutics AB (publ) Competitors List
Related Companies and Tools
